The latest selling price of deuterated colexitinib in 2025

Deucravacitinib is a new oral tyrosine kinase inhibitor mainly used to treat moderate to severe plaque psoriasis. The drug effectively modulates immune responses, reduces inflammation and improves skin conditions by selectively inhibiting tyrosine kinase 2 (TYK2). In recent years, with the increasing demand for psoriasis treatment, the application of deuterated colexitinib has gradually attracted attention.

In China, the original research version of deuterated colexitinib has been approved for marketing and has been included in the reimbursement list of the national medical insurance. The implementation of this policy allows many patients to obtain effective treatment at a relatively low cost. The latest information shows that the price of deuterated coxitinib is about more than 1,000 yuan for 6mg 7 tablets, while the original research version of 6mg 30 tablets is priced as high as 50,000 yuan. However, these prices are subject to change due to fluctuations in international exchange rates.

In addition to the original version, deuterated colexitinib also has generic versions in some other countries. For example, the ingredients of generic drugs that have been officially launched in countries such as Laos and Bangladesh are basically the same as those of the original drugs, and the price is relatively cheap. 6mg*30 tablets are priced at around 400 to 500 yuan. This undoubtedly provides more choices for patients with limited financial conditions, while also meeting the needs of different markets.

Clinical trial results of deuterated colexitinib show that the drug performs well in improving patients' skin lesions, reducing itching and improving quality of life. Compared with traditional treatment methods, deuterated colexitinib is more convenient to use, and its oral administration form simplifies the treatment process. In addition, because of its favorable safety and tolerability profile, deuterated colexitinib is increasingly becoming a recommended treatment option for patients with psoriasis.

Reference materials:https://go.drugbank.com/drugs/DB16650